Liftstream is an executive search recruitment company in the life sciences sector
Biopharma Boards Require Lead Independent Directors
Biopharma Bucking the Trend for Separating Board Chair and CEO
Liftstream Addressing the Chair and CEO Power Axis
UK shows multi-stakeholder approach tackles diversity
The UK has been seriously tackling the issue of diversity in the senior ranks of British business. The Davies Review, led by the charismatic but challenging Lord Mervyn Davies, pushed UK boards to get 25% of women on the boards of FTSE 100 companies. This triggered concerted action on the part of the nominated companies because they would be publicly measured, and reported.
Hacked By GeNErAL
HemaFlo Therapeutics Names Michael Martino as CEO
HemaFlo Therapeutics, a private biotech company based in Carlsbad, Calif, has appointed Michael A. Martino as President, CEO and Board Director. Martino joined as President and CEO of Ambit Biosciences after its acquisition by Daiichi Sankyo in 2014.
Gurnet Point Capital Launches Boston Pharmaceuticals
Gurnet Point Capital, a Cambridge, MA-based US healthcare and life sciences investment firm, has founded Boston Pharmaceuticals, a fully integrated drug development company with a $600 million commitment. Christopher Viehbacher, the Managing Partner of Gurnet Point Capital and the former CEO of Sanofi, was appointed as Boston Pharmaceuticals’ Chairman. Robert Armstrong, the former head of external R&D at Chorus (Eli Lilly), was named CEO.
Women Executives: Stepping Up to the C-suite and Board (Event Schedule)
Thursday, December 3, 2015 from 4:00 PM to 7:30 PM (EST)
Biogen, Bio-9 Building, 300 Binney Street Cambridge, MA 02142 – View Map
Atlas Maps Path Towards Unlocking Gender Potential
Last month, Atlas Ventures investor and blogger Bruce Booth, penned a tremendous analysis of gender inequality in the biotech sector. I recommend you read it here. He made the case for a far greater level of women participation at the C-suite and Board level of biotechnology companies, and openly discussed the perceived shortcomings that Atlas Ventures has in this area of leadership appointments among its portfolio firms.